Mercimek-Mahmutoglu Saadet, Sidky Sarah, Hyland Keith, Patel Jaina, Donner Elizabeth J, Logan William, Mendoza-Londono Roberto, Moharir Mahendranath, Raiman Julian, Schulze Andreas, Siriwardena Komudi, Yoon Grace, Kyriakopoulou Lianna
Division of Clinical and Metabolic Genetics, Department of Pediatrics, University of Toronto, The Hospital for Sick Children, Toronto, Canada.
Genetics and Genome Biology, Research Institute, The Hospital for Sick Children, Toronto, Canada.
Orphanet J Rare Dis. 2015 Feb 8;10:12. doi: 10.1186/s13023-015-0234-9.
Inherited neurotransmitter disorders are primary defects of neurotransmitter metabolism. The main purpose of this retrospective cohort study was to identify prevalence of inherited neurotransmitter disorders.
This retrospective cohort study does not have inclusion criteria; rather included all patients who underwent cerebrospinal fluid (CSF) homovanillic and 5-hydroxyindol acetic acid measurements. Patients with CSF neurotransmitter investigations suggestive of an inherited neurotransmitter disorder and patients with normal or non-diagnostic CSF neurotransmitter investigations underwent direct sequencing of single gene disorders.
There were 154 patients between October 2004 and July 2013. Four patients were excluded due to their diagnosis prior to this study dates. Two major clinical feature categories of patients who underwent lumbar puncture were movement disorders or epilepsy in our institution. Twenty out of the 150 patients (13.3%) were diagnosed with a genetic disorder including inherited neurotransmitter disorders (6 patients) (dihydropteridine reductase, 6-pyruvoyl-tetrahydropterin synthase, guanosine triphosphate cyclohydrolase I, tyrosine hydroxylase, pyridoxine dependent epilepsy due to mutations in the ALDH7A1 gene and pyridoxamine-5-phosphate oxidase deficiencies) and non-neurotransmitter disorders (14 patients).
Prevalence of inherited neurotransmitter disorders was 4% in our retrospective cohort study. Eight out of the 150 patients (5.3%) had one of the treatable inherited metabolic disorders with favorable short-term neurodevelopmental outcomes, highlighting the importance of an early and specific diagnosis. Whole exome or genome sequencing might shed light to unravel underlying genetic defects of new inherited neurotransmitter disorders in near future.
遗传性神经递质疾病是神经递质代谢的原发性缺陷。这项回顾性队列研究的主要目的是确定遗传性神经递质疾病的患病率。
这项回顾性队列研究没有纳入标准;而是纳入了所有接受脑脊液(CSF)高香草酸和5-羟吲哚乙酸测量的患者。脑脊液神经递质检查提示遗传性神经递质疾病的患者以及脑脊液神经递质检查正常或未明确诊断的患者接受了单基因疾病的直接测序。
2004年10月至2013年7月期间共有154例患者。4例患者因在本研究日期之前已确诊而被排除。在我们机构接受腰椎穿刺的患者主要有两个临床特征类别,即运动障碍或癫痫。150例患者中有20例(13.3%)被诊断患有遗传性疾病,包括遗传性神经递质疾病(6例)(二氢蝶啶还原酶、6-丙酮酰四氢蝶呤合酶、鸟苷三磷酸环化水解酶I、酪氨酸羟化酶、由于ALDH7A1基因突变导致的维生素B6依赖性癫痫以及磷酸吡哆胺-5-磷酸氧化酶缺乏)和非神经递质疾病(14例)。
在我们的回顾性队列研究中,遗传性神经递质疾病的患病率为4%。150例患者中有8例(5.3%)患有可治疗的遗传性代谢疾病之一,且短期神经发育结局良好,这凸显了早期和特异性诊断的重要性。全外显子组或基因组测序可能在不久的将来有助于揭示新的遗传性神经递质疾病的潜在遗传缺陷。